17-ODYA | CAS 34450-18-5

Name: 17-ODYA
Brand: BOC Sciences
Rating: 5 (1 reviews)

Catalog Number	R01-0053
Category	Alkynes
Molecular Formula	C18H32O2
Molecular Weight	280.45

Inquiry

* Please be kindly noted products are not for therapeutic use. We do not sell to patients.

Worldwide Delivery
Quality Assurance
24/7 Customer Service

Product Introduction

17-Octadecynoic acid is a suicide inhibitor of LTB4 ω-oxidase. 17-ODYA can completely inhibit the bradykinin-dependent transport of sodium chloride in rat TALH cells at a concentration of 10 µM.

Chemical Information
Product Specification
Application

Synonyms	Alkynyl Stearic Acid;17-Octadecynoic acid
Purity	≥98% by HPLC
IUPAC Name	octadec-17-ynoic acid
Canonical SMILES	C#CCCCCCCCCCCCCCCCC(=O)O
InChI	InChI=1S/C18H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h1H,3-17H2,(H,19,20)
InChIKey	DZIILFGADWDKMF-UHFFFAOYSA-N

Storage

Powder, -20°C, 3 years; In solvent, -80°C, 6 months; -20°C, 1 month

17-ODYA, also known as 17-octadecynoic acid, serves as a potent chemical inhibitor targeting cytochrome P450 enzymes, particularly those of the CYP4 family. Here are four pivotal applications of 17-ODYA:

Cardiovascular Research: Delving into cardiovascular studies, 17-ODYA plays a crucial role in unraveling the intricate mechanisms by which cytochrome P450 enzymes influence blood pressure regulation and vascular function. Through the inhibition of CYP4 enzymes, researchers embark on a journey to explore the impact of these enzymes on the synthesis of vasoactive substances. This exploration fosters a deeper comprehension of the underlying factors contributing to hypertension and various vascular maladies, paving the way for advanced treatments.

Cancer Research: In the realm of oncology, 17-ODYA emerges as a pivotal tool for navigating the complex metabolic pathways intertwined with cancer progression and treatment resistance. By targeting CYP4A enzymes, researchers gain valuable insights into the interplay between fatty acid metabolism and the relentless growth and metastasis of tumors. This inhibition mechanism uncovers novel therapeutic targets and amplifies the arsenal of anti-cancer strategies, heralding a new era of precision medicine in the fight against cancer.

Neuropharmacology: Unlocking the mysteries of neuropharmacology, 17-ODYA stands at the forefront of studying the pivotal role played by brain P450 enzymes in neuroinflammation, neuroprotection, and the regulation of brain function. Through the strategic inhibition of these enzymes, researchers embark on a profound journey into the metabolic pathways that impact neuronal well-being and disease states. This critical exploration fuels the development of advanced treatments for neurological conditions like stroke, Alzheimer’s disease, and epilepsy.

Toxicology Studies: Within the realm of toxicology, 17-ODYA emerges as a vital instrument for unraveling the intricate metabolic degradation pathways of diverse xenobiotics and endogenous compounds. By selectively inhibiting specific cytochrome P450 enzymes, this compound serves as a beacon of illumination, shedding light on how these pathways intricately govern the bioactivation and detoxification of toxic substances. This application proves indispensable in the evaluation of the safety and efficacy of novel drugs and environmental chemicals.